JP2023509966A - 腫瘍溶解性ウイルス様小胞の組成物および使用方法 - Google Patents

腫瘍溶解性ウイルス様小胞の組成物および使用方法 Download PDF

Info

Publication number
JP2023509966A
JP2023509966A JP2022542209A JP2022542209A JP2023509966A JP 2023509966 A JP2023509966 A JP 2023509966A JP 2022542209 A JP2022542209 A JP 2022542209A JP 2022542209 A JP2022542209 A JP 2022542209A JP 2023509966 A JP2023509966 A JP 2023509966A
Authority
JP
Japan
Prior art keywords
sequence
viral vector
vlv
encoding
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509966A5 (cg-RX-API-DMAC7.html
Inventor
ビジャン アルマシアン,
ヴァレリアン ナカール,
シャンヨン マ,
バースカラ レディ マディナ,
ケペン ワン,
ティムール ヤロヴィンスキー,
Original Assignee
カロジェン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カロジェン コーポレイション filed Critical カロジェン コーポレイション
Publication of JP2023509966A publication Critical patent/JP2023509966A/ja
Publication of JP2023509966A5 publication Critical patent/JP2023509966A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20244—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022542209A 2020-01-10 2021-01-08 腫瘍溶解性ウイルス様小胞の組成物および使用方法 Pending JP2023509966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959435P 2020-01-10 2020-01-10
US62/959,435 2020-01-10
PCT/US2021/012834 WO2021142366A1 (en) 2020-01-10 2021-01-08 Compositions and methods of use of oncolytic virus like vesicles

Publications (2)

Publication Number Publication Date
JP2023509966A true JP2023509966A (ja) 2023-03-10
JP2023509966A5 JP2023509966A5 (cg-RX-API-DMAC7.html) 2024-01-15

Family

ID=74595378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542209A Pending JP2023509966A (ja) 2020-01-10 2021-01-08 腫瘍溶解性ウイルス様小胞の組成物および使用方法

Country Status (5)

Country Link
US (1) US12577585B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087858A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023509966A (cg-RX-API-DMAC7.html)
CN (1) CN115397838A (cg-RX-API-DMAC7.html)
WO (1) WO2021142366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性b型肝炎感染症を処置または防止するための複数抗原治療ワクチン
JP2025508866A (ja) * 2022-02-22 2025-04-10 ヴァイロ バイオ インク. 腫瘍溶解性ウイルスおよび使用方法
JP2025506732A (ja) * 2022-02-22 2025-03-13 カロジェン コーポレイション 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞(vlv)プラットフォーム
CN117327709A (zh) * 2022-06-24 2024-01-02 深圳瑞吉生物科技有限公司 用于实体肿瘤的治疗性mRNA及其应用
US20260034208A1 (en) * 2022-07-26 2026-02-05 Yale University Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
IL320318A (en) * 2022-10-19 2025-06-01 Kalivir Immunotherapeutics Inc Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof
WO2024119388A1 (zh) * 2022-12-07 2024-06-13 上海鑫湾生物科技有限公司 一种用于共表达多种目的基因的构建体及其用途
CN118831091A (zh) * 2023-04-11 2024-10-25 浙江自贸区红岸基地生物科技有限公司 一种saRNA递送系统及其制备方法和应用
WO2025208054A1 (en) * 2024-03-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Recombinant rhabdovirus encoding interleukin-12 (il-12)
CN120733012B (zh) * 2024-08-20 2026-08-07 浙江大学 基于mRNA及蛋白编码的肿瘤药物、制备方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500325A (ja) * 1999-05-17 2004-01-08 シェーリング コーポレイション 細胞増殖障害を処置するための組成物および方法
JP2017515509A (ja) * 2014-05-16 2017-06-15 イエール ユニバーシティ ワクチン用途のための高力価ウイルス様ベシクルの進化の方法
JP2017515508A (ja) * 2014-05-16 2017-06-15 イエール ユニバーシティ 慢性b型肝炎ウイルス(hbv)感染症を予防または処置するためのウイルス様ベシクル(vlv)ベースのワクチン
JP2019527737A (ja) * 2016-08-09 2019-10-03 アルケヤール, アルモハナッドALKAYYAL, Almohanad Il12を発現する腫瘍溶解性ラブドウイルス

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862982B1 (fr) 2003-12-02 2006-04-28 Genethon Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale.
AU2007342333B2 (en) * 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
GB2460265A (en) 2008-05-23 2009-11-25 Univ Dublin City Detection assembly
EP3437654B1 (en) 2016-03-31 2023-09-20 Centro De Ingeniería Genética Y Biotecnología Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
PT3684786T (pt) 2017-09-22 2024-10-30 Centre Nat Rech Scient Glicoproteína mutante do vírus da estomatite vesicular

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500325A (ja) * 1999-05-17 2004-01-08 シェーリング コーポレイション 細胞増殖障害を処置するための組成物および方法
JP2017515509A (ja) * 2014-05-16 2017-06-15 イエール ユニバーシティ ワクチン用途のための高力価ウイルス様ベシクルの進化の方法
JP2017515508A (ja) * 2014-05-16 2017-06-15 イエール ユニバーシティ 慢性b型肝炎ウイルス(hbv)感染症を予防または処置するためのウイルス様ベシクル(vlv)ベースのワクチン
JP2019527737A (ja) * 2016-08-09 2019-10-03 アルケヤール, アルモハナッドALKAYYAL, Almohanad Il12を発現する腫瘍溶解性ラブドウイルス

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J VIROL, vol. 89, no. 20, JPN6025003197, 5 August 2015 (2015-08-05), pages 10407 - 10415, ISSN: 0005674075 *
外科と代謝・栄養, vol. 53, no. 5, JPN6025003198, 2019, pages 267 - 270, ISSN: 0005784434 *
日薬理誌, vol. 142, JPN6025003196, 2013, pages 85 - 88, ISSN: 0005674076 *

Also Published As

Publication number Publication date
WO2021142366A1 (en) 2021-07-15
US20230063041A1 (en) 2023-03-02
CN115397838A (zh) 2022-11-25
US12577585B2 (en) 2026-03-17
EP4087858A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
US12577585B2 (en) Compositions and methods of use of oncolytic virus like vesicles
RU2719190C2 (ru) Онколитический hsv-вектор
FI118011B (fi) Menetelmä replikaatiokyvyn suhteen puutteellisen yhdistelmä-DNA-adenoviruksen tuottamiseksi
JP7038065B2 (ja) 腫瘍溶解性ウイルス株
KR102409147B1 (ko) 종양분해성 백시니아 바이러스
Atkins et al. Therapeutic and prophylactic applications of alphavirus vectors
CN109576231B (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US10435712B2 (en) Evolution of high-titer virus-like vesicles for vaccine applications
WO2014047350A1 (en) Oncolytic virus encoding pd-1 binding agents and uses of the same
WO2018171103A1 (zh) 可编程的溶瘤病毒疫苗系统及其应用
JP7132339B2 (ja) 腫瘍を治療するための仮性狂犬病ウイルス
JP2006519784A (ja) 原発癌および転移癌に対する治療(a2)温熱療法と腫瘍溶解の同時治療(a3)
KR20220125806A (ko) 재조합 백시니아 바이러스
KR20250130586A (ko) Hpv 감염-관련 질병을 예방 또는 치료하기 위한 폴리뉴클레오티드 분자
KR102768669B1 (ko) 종양 치료용 콕삭키바이러스 b
CN116133671A (zh) 重组牛痘病毒
CN114657150A (zh) 用于改善免疫疗法的重组溶瘤腺病毒及其应用
KR102818964B1 (ko) 종양 치료용 에코바이러스
JP4423507B2 (ja) 癌遺伝子治療薬
WO2024026274A2 (en) Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
CN118813708A (zh) 双靶点溶瘤腺病毒载体及其制备方法和应用
CN1517437B (zh) 特异性治疗肿瘤或胞内感染的疫苗及应用
CN121344098A (zh) Gbm靶向性溶瘤腺病毒载体及其构建方法和应用
HK40091930A (zh) 一种增强向肿瘤部位浸润能力的car-nk细胞制备及应用
HK40088967A (en) Recombinant vaccinia virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260129